Introduction {#s1}
============

Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection ([@B44]). It is the major cause of death in intensive care units ([@B35]). Epidemiological studies in the United States have shown that 750,000 cases are diagnosed with severe sepsis annually, and 215,000 deaths occur every year ([@B1]). Owing to advances in the management of sepsis, such as early fluid resuscitation, early administration of antibiotics, and advances in supportive care, such lung-protective mechanical ventilation, the risk of sepsis-associated death has been decreasing. However, the mortality of sepsis remains high ([@B46]).

The mechanism of sepsis is complicated ([@B2]; [@B36]). Sepsis initiates a complex interplay of host pro-inflammatory and anti-inflammatory processes ([@B19]; [@B8]). Simultaneously, both inflammatory response and immunosuppression are involved in sepsis ([@B19]; [@B17]). Serum concentrations of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-8 (IL-8), and many other cytokines or chemokines are increased after the onset of sepsis ([@B8]; [@B40]). Immunoparalysis caused by the apoptosis of many immune cells, including T cells, B cells, dendritic cells, and neutrophils, is another dominant problem in sepsis patients; this state in turn results in a depressed immune system and failure in the elimination of pathogens and maintenance of immune balance ([@B19]; [@B14]). Furthermore, anti-apoptosis therapy by blocking receptors or inhibitors of apoptotic pathway can reduce mortality in sepsis models ([@B60]; [@B16]). Blocking of programmed cell death receptor-1 (PD-1) also demonstrated a potential toward the reduction of sepsis-associated mortality ([@B60]; [@B19]; [@B38]).

It is known that serine proteases are involved in systemic inflammation and cell apoptosis ([@B54]; [@B53]). Urinary trypsin inhibitor (also called ulinastatin or UTI) is an important protease inhibitor found in human urine, blood, and other tissues ([@B31]). It has been shown that UTI plays an anti-inflammatory role by decreasing the phosphorylation of p38 mitogen-activated protein kinase (p38-MAPK) and nuclear factor-κB (NF-κB) activation as well as an anti-apoptotic role by protecting the mitochondria and scavenging oxygen free radicals ([@B43]; [@B29]). The study of UTI mechanism revealed that UTI can decrease the level of inflammatory mediators and reduce the frequency of immune cell apoptosis in sepsis models. Therefore, UTI has been proposed as a potentially new therapeutic option for the treatment of sepsis and multiple organ dysfunction syndrome (MODS) ([@B31]; [@B3]).

Recently, clinical trials in sepsis patients treated with UTI or UTI combined with thymosin α1 showed a survival benefit trend ([@B55]; [@B26]). Meanwhile, five meta-analysis of studies in sepsis patients either UTI administration alone or a combination of UTI and thymosin α1 have been published ([@B15]; [@B28]; [@B13]; [@B52]; [@B34]). Among these five meta-analysis, two meta-analysis ([@B13]; [@B34]) analyzed the effect of using UTI alone and no significant difference between UTI group and control group in the 28-day mortality. Given that the results of these two meta-analysis are based on subgroup analysis, which included the same two trials ([@B55]; [@B26]), it is difficult to prove the effect of UTI alone. At present, it remains unclear whether the beneficial impact is rendered by UTI, thymosin α1, or the combination. Therefore, we pooled the randomized controlled trials that involved the use of UTI alone in order to clarify the efficacy of UTI in sepsis.

Materials and Methods {#s2}
=====================

In accordance to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) statement for reporting systematic reviews and meta-analysis ([@B30]), two groups of the present authors \[(HW and LY) and (YT and BH)\] independently conducted literature searches, established the study inclusion and exclusion criteria, performed quality assessment, and extracted data. If a consensus was not reached, it was resolved by the senior authors (ZL and PC). The flow graph is shown in [**Figure 1**](#f1){ref-type="fig"}.

![Flow diagram of the study selection process.](fphar-10-01370-g001){#f1}

Study Registration {#s2_1}
------------------

Registration number in PROSPERO: CRD42018110751, an international prospective register of systematic reviews.

Search Strategy {#s2_2}
---------------

We searched for randomized controlled trials in sepsis published on or before September 01, 2018, regardless of language, publication type, or study region. The electronic database includes PubMed, Medline, Embase, and China National Knowledge Infrastructure (CNKI). The key words that were searched and their combinations in (title/abstract) are shown in [**Table 1**](#T1){ref-type="table"}.

###### 

Search terms and phrases used in the meta-analysis.

  ------------------------------------------------
  \#1 ulinastatin
  \#2 UTI
  \#3 urinary protease inhibitor
  \#4 sepsis
  \#5 sept\*mia
  \#6 effect\*
  \#7 treatment
  \#8 therap\*
  \#9 Systemic Inflammatory Response Syndrome
  \#10 SIRS
  \#11 MODS
  \#12 Multiple organ dysfunction syndrome
  \#11 \#1or \#2 or \#3
  \#12 \#4 or \#5 or \#9 or \#10 or \#11 or \#12
  \#13 \#11 and \#12 and \#6
  \#14 \#11 and \#12 and \#7
  ------------------------------------------------

The means of \"\*\" is truncation.

Selection Criteria {#s2_3}
------------------

Studies were included if they met the following criteria: 1) participants: patients who were diagnosed with sepsis, severe sepsis, or septic shock; 2) type of interventions: use of UTI alone regardless of treatment duration; 3) research design: either randomized controlled trial (RCT) or prospective cohort study. Review articles, animal experimental studies, case reports, and letters that did not describe outcomes or were not published as full reports were excluded. In addition, we only included the most updated and completed studies in case of duplicated publication.

Outcomes and Data Extraction {#s2_4}
----------------------------

The primary outcome was all-cause mortality. The secondary outcomes were changes in the serum levels of IL-6, IL-10, and TNF-α, the incidence rate of MODS, and changes in Acute Physiology, Age, Chronic Health Evaluation II (APACHE II) scores. We also collected the following information: study design, year of study, country, study period, the number of patients included, intervention methods, and adverse events. The main characteristics of the included studies are shown in [**Table 2**](#T2){ref-type="table"}. For the continuous variables, we acquired data according to the following method. For calculating the mean in this meta-analysis, we employed the formula X = X~2~ - X~1~, where X represents the mean applied in this meta-analysis, X1 represents the baseline mean, and X2 represents the endpoint mean. For calculating the standard deviation (SD) in this metaanalysis, we chose to employ the formula $S^{2} = S_{1}^{2} + S_{2}^{2} - 2 \times R\, \times S_{1}\, \times S_{2}$, where S represents the standard deviation applied in this meta-analysis, S1 represents the baseline SD, and S~2~ represents the endpoint SD. R = 0.5 in the meta-analysis, which was described in the Cochrane Handbook. All data were independently extracted by two authors (HW and LY). HW entered data into the computer and LY checked them.

###### 

The characteristics of the included studies.

  Author (year published)   Country   Study period      Study Type   Total No. of patients   Number of patients   Mean Age, yrs   Diagnosis       Interventions   Outcomes                     Adverse effects             Quality score                                                                                                                                          
  ------------------------- --------- ----------------- ------------ ----------------------- -------------------- --------------- --------------- --------------- ---------------------------- --------------------------- ---------------------------- ---------------------------------------------------- ----------------------------------------- -------------------------- ---------
  [@B11]                    China     2013.03-2015.05   RCT          96                      49                   47              56.7 ± 12.5     59.3 ± 11.6     severe sepsis                30,0000 IU q8h×5d           Antibiotics standard care    28-day all-cause mortality                           PCT, CRP, IL-6, TNF-a                     none                       ?☆☆☆☆☆
  [@B7]                     India     2012.10-2014.05   RCT          104                     68                   36              P \> 0.05       sepsis          NR                           NR                          28-day all-cause mortality   VDs, length of ICU stay, VASDs, occurrence of MODS   none                                      ☆☆☆                        
  [@B26]                    India     2009.09-2010.06   RCT          114                     55                   59              37.5 ± 12.9     36.7 ± 12.5     sepsis                       20,0000 IU q12h×5d          equivalent normal saline     28-day all-cause mortality                           VDs VFDs hospital stay, APACHE II score   none                       ☆☆☆☆☆☆☆
  [@B56]                    China     2011.10-2012.10   RCT          60                      30                   30              54.3 ± 16.2     sepsis          30,0000 IU q8h×5d            equivalent normal saline    28-day all-cause mortality   MODS,IL-10,IL-6 CD4,CD25,IL-17,HLA-DR                none                                      ☆☆☆☆☆                      
  [@B48]                    Korea     2005.01-2008.06   PC           169                     43                   126             61 ± 18         61 ± 17         severe sepsis septic shock   100,0000 IU qd              Antibiotics standard care    mortality                                            SOFA score                                none                       ☆☆☆
  [@B42]                    China     NR                RCT          60                      30                   30              43.3 ± 9.2      sepsis          10,0000 IU q8h×5d            Antibiotics standard care   mortality                    IL-6, IL-10, TNF-a, CRP                              none                                      ☆☆☆☆☆☆                     
  [@B39]                    India     2014.10-2017.10   PO           225                     87                   138             P \> 0.05       sepsis          20,0000 IU q12h×5d           Antibiotics standard care   all-cause mortality          VFDs VASFDs                                          none                                      ☆☆☆                        
  [@B6]                     China     2013.07-2014.06   RCT          50                      25                   25              43.6 ± 5.8      41.7 ± 3.8      severe sepsis                20,0000 IU q12h×7 d         equivalent normal saline     28-day all-cause mortality                           IL-8,TNF-α,IL-6,IL-10                     none                       ☆☆☆☆
  [@B49]                    China     NR                RCT          74                      37                   37              31-52           severe sepsis   20,0000 IU q12h×7d           equivalent normal saline    all-cause mortality          IL-8, TNF-α,IL-6,IL-10                               none                                      ☆☆☆☆                       
  [@B24]                    China     2001.12-2005.12   RCT          78                      39                   39              56 ± 21         54 ± 16         Severe sepsis septic shock   20,0000 IU qd×3d            equivalent normal saline     NR                                                   IL-8,IL-1, TNF-α,IL-6                     none                       ☆☆☆☆
  [@B37]                    China     2006.1-2007.2     RCT          42                      21                   21              60.18 ± 19.08   59.39 ± 21.11   severe sepsis                10000 IU/kg/d q12h×5d       equivalent normal saline     28-day mortality                                     IL-10, TNF-α, APACHE II score             none                       ☆☆☆☆☆
  [@B10]                    China     2003.09-2004.02   RCT          56                      28                   28              57 ± 16         61 ± 16         sepsis                       20,0000 IU q12h×5d          equivalent normal saline     28-day mortality                                     IL-8, TNF-α,IL-6, APACHE II score         rash                       ☆☆☆☆
  [@B9]                     China     2013.07-2014.06   RCT          86                      43                   43              59.45 ± 6.54    59.32 ± 6.15    severe sepsis                20,0000 IU q12h×5d          equivalent normal saline     NR                                                   IL-8, TNF-α,IL-10, APACHE II score        nausea, fatigue and rash   ☆☆☆☆☆
  [@B51]                    China     2004.1-2006.12    RCT          84                      44                   40              55.3 ± 24.5     52.1 ± 16.3     sepsis                       20,0000 IU q12h×7d          equivalent normal saline     NR                                                   TNF-α,IL-6,IL-10,IL-8,IL-1                none                       ☆☆☆☆
  [@B57]                    China     2011-2012         RCT          60                      31                   29              48.71 ± 30.15   50.09 ± 29.11   sepsis                       20,0000 IU q8h×8d           equivalent normal saline     28-day mortality                                     TNF-α,IL-10 APACHE II score               None                       ☆☆☆☆

RCT, Randomized controlled study; PC, prospective case--control study, PO, prospective observational study; p \> 0.05, no difference in the baseline of mean age; VFDs, ventilator-free days; VDs, ventilator days; VASFDs, vasopressor-free days; VASDs, vasopressor days; NR, It was not given in the original article.

Quality Assessment {#s2_5}
------------------

First, two reviewers independently assessed the eligibility of articles identified during the initial search strategy. Then, the quality of all included studies was evaluated according to the modified Jadad scale, which can intuitively assess the quality of the included RCTs ([@B23]). The studies were rated as low quality and high quality under scores of 1--3 and 4--7, respectively. In this meta-analysis, three studies were regarded as low quality and 12 studies were regarded as high quality. Moreover, detailed scoring results are shown in [**Table 3**](#T3){ref-type="table"}.

###### 

The modified Jadad questionnaire for the included studies.

  Study, year (Station)   Random sequence production   Allocation concealment   Blinding metod   Withdrawals and dropouts   Score                            
  ----------------------- ---------------------------- ------------------------ ---------------- -------------------------- ------- -- -- --- --- -- --- --- ---
  [@B51]                                               1                                                                    1             2              0   4
  [@B24]                                               1                                                                    1             2              0   4
  [@B26]                                               2                                                                    2             2          1       7
  [@B56]                                               2                                                                    1             2              0   5
  [@B48]                                               1                                                                    1                 1          0   3
  [@B57]                                               1                                                                    1             2              0   4
  [@B9]                                                2                                                                    1             2              0   5
  [@B49]                                               1                                                                    1             2              0   4
  [@B6]                                                1                                                                    1             2              0   4
  [@B10]                                               1                                                                    1             2              0   4
  [@B37]                                               2                                                                    1             2              0   5
  [@B42]                  2                                                                      2                                        2              0   6
  [@B11]                  2                                                                      2                                        2              0   6
  [@B39]                                               1                                                                    1                 1          0   3
  [@B7]                                                1                                                                    1                 1          0   3

1--3 score, low quality; 4--7 score, high quality.

Statistical Analysis {#s2_6}
--------------------

In this meta-analysis, all statistical calculations and analysis were performed using Review Manager 5.3 (Cochrane collaboration, Oxford, UK). According to the results of statistical analysis, we divided the type of data into dichotomous and continuous. For the dichotomous data, such as mortality, the incidence of MODS, and adverse events, we calculated the odds ratios (OR), 95% confidence intervals (CIs) of every included study, and the overall Mantel--Haenszel (M-H). For the continuous data, such as IL-6, IL-10, and TNF-α levels and the APACHE II score, we calculated the mean difference (MD) and 95% CIs. The statistical heterogeneity was examined using chi-square and I^2^ statistical tests as well as P values. At first, we used a fixed-effects model, but then chose to employ the random-effects model if I^2^ was ≥50%.

Because patients with sepsis have a high mortality rate and not all studies report a 28-day mortality rate, we chose all-cause mortality to be our primary outcome. Sensitivity analysis was used to judge whether the study results were statistically significant. For eliminating publication bias, we used the funnel plot method.

Results {#s3}
=======

Description of Eligible Studies {#s3_1}
-------------------------------

We identified 15 ([@B10]; [@B24]; [@B51]; [@B37]; [@B48]; [@B49]; [@B56]; [@B26]; [@B6]; [@B9]; [@B57]; [@B11]; [@B7]; [@B42]; [@B39]) potential studies that included a total of 1358 patients: 630 patients in the UTI group and 728 patients in the control group. Thirteen RCTs and two prospective studies were included in this meta-analysis. The specific method for identifying studies and establishing the inclusion and exclusion criteria is shown in [**Figure 1**](#f1){ref-type="fig"}. Eleven studies were published from China, three from India, and one from Korea.

Primary Outcomes {#s3_2}
----------------

### All-Cause Mortality {#s3_2_1}

We extracted the data from 12 studies ([@B10]; [@B42]; [@B37]; [@B48]; [@B49]; [@B56]; [@B26]; [@B6]; [@B7]; [@B57]; [@B11]; [@B39]) and 1110 participants were classified into two groups to assess all-cause mortality. All-cause mortality was significantly lower in the UTI group than in the control group (OR = 0.48, 95% CI \[0.35, 0.66\], p \< 0.00001), and heterogeneity was low (x^2^ = 12.57, p = 0.32, I^2^ = 13%). The results are shown in [**Figure 2**](#f2){ref-type="fig"}.

![All-cause mortality of the included studies.](fphar-10-01370-g002){#f2}

Secondary Outcomes {#s3_3}
------------------

### Levels of IL-6 {#s3_3_1}

We obtained the related data from eight studies ([@B10]; [@B42]; [@B24]; [@B51]; [@B49]; [@B56]; [@B6]; [@B11]) (558 participants in two groups) to analyze the serum levels of IL-6. The serum level of IL-6 at the time of hospital admission was not different between the UTI and control groups. After treatment, IL-6 was significantly less in the UTI group than in the control group (MD = −53.00, 95% CI \[−95.56,−10.05\], p = 0.02), and a obvious heterogeneity in the results was observed (x^2^ = 410.24, p \< 0.00001, I^2^ = 98%). The results are shown in [**Figure 3A**](#f3){ref-type="fig"}.

![Ulinastatin regulates the levels of pro-inflammatory and anti-inflammatory cytokines. Pro-inflammatory factor: IL-6 **(A)**, TNF-α **(B)**. Anti-inflammatory factors: IL-10 **(C)**.](fphar-10-01370-g003){#f3}

### Levels of TNF-α {#s3_3_2}

We collected the related data from ten studies ([@B10]; [@B42]; [@B24]; [@B51]; [@B37]; [@B49]; [@B6]; [@B9]; [@B57]; [@B11]) (686 participants in two groups) to analyze the serum levels of TNF-α. The level of TNF-α at the time of hospital admission was not different between the UTI and control groups. After treatment, TNF-α was significantly less in the UTI group than in the control group (MD = −53.05, 95% CI \[−68.36, −37.73\], p \< 0.00001), and an obvious heterogeneity was observed in the results (x^2^ = 43.58, p \< 0.00001, I^2^ = 79%). The results are shown in [**Figure 3B**](#f3){ref-type="fig"}.

### Levels of IL-10 {#s3_3_3}

We gained the related data from nine studies ([@B10]; [@B42]; [@B51]; [@B37]; [@B49]; [@B56]; [@B6]; [@B9]; [@B57]) (572 participants in two groups) to analyze the serum levels of IL-10. The serum level of IL-10 at the time of hospital admission was not different between the UTI and control groups. After treatment, IL-10 was significantly greater in the UTI group than in the control group (MD = 37.73, 95% CI \[16.92, 58.54\], p = 0.0004), and an obvious heterogeneity was observed in the results (x^2^ = 329.55, p \< 0.0001, I^2^ = 98%). The results are shown in [**Figure 3C**](#f3){ref-type="fig"}.

The Apache II Score {#s3_4}
-------------------

The APACHE II scores at the time of hospital admission were not different between the UTI and control groups. We extracted the data from four studies ([@B37]; [@B10]; [@B9]; [@B57]) (244 participants in two groups) to assess this change. After treatment, the APACHE II scores were significantly less in the UTI group than in the control group MD = −3.18, 95%CI \[−4.01, −2.35\], p \< 0.00001), and heterogeneity was low (x^2^ = 4.51, p = 0.21, I^2^ = 33%). The results are shown in [**Figure 4**](#f4){ref-type="fig"}.

![Ulinastatin reduces the APACHE II score of sepsis patients.](fphar-10-01370-g004){#f4}

The Incidence of MODS {#s3_5}
---------------------

We extracted the data from three studies ([@B42]; [@B26]; [@B39]) (399 participants in included in two groups) to assess the incidence of MODS. After treatment, the incidence of MODS was significantly less in the UTI groups than in the control groups (OR = 0.3, 95% CI \[0.18--0.49\], p \< 0.00001), and heterogeneity was not observed in the results (x^2^ = 0.58, p = 0.75, I^2^ = 0%). The result is shown in [**Figure 5**](#f5){ref-type="fig"}.

![Ulinastatin reduces the incidence of multiple organ dysfunction syndrome (MODS).](fphar-10-01370-g005){#f5}

Publication Bias and Sensitivity Analysis {#s3_6}
-----------------------------------------

All included studies involved the use of UTI for treating sepsis patients. Using all-cause mortality as the main variable, the included studies were evaluated for the effect of study size. The funnel plot demonstrated a balanced and or a symmetrical shape, suggesting no significant publication bias. In addition, Egger's test also demonstrated a statistically significant symmetry (p = 0.183). Therefore, the potential publication bias had no significant influence on the results ([**Figure 6**](#f6){ref-type="fig"}).

![The Begg's test and Egger's test for all-cause-mortality. Begg's test: rank correlation test; Egger's test: linear regression method; ES, effect size; 95% CI, 95% confidence interval.](fphar-10-01370-g006){#f6}

Sensitivity analysis was conducted by the leave-one-out method and checking the consistency of the overall effect estimate. For IL-6, we found that the I^2^ value decreased to 0% after excluding the studies conducted by [@B42] and [@B56]. For TNF-α, we found that the I^2^ value decreased to 54% after excluding the studies conducted by [@B49] and [@B51]. For IL-10, we found that the I^2^ value decreased up to 84% after removing the study by [@B42], [@B51] and [@B56]. We believe that the high heterogeneity may arise from factors such as sample size, different measuring instruments, and design methods.

Discussion {#s4}
==========

UTI is a multifunctional Kunitz-type serine protease inhibitor found in human urine and blood. UTI is a member of inter-a-inhibitor (IaI) family, which is produced by hepatocytes ([@B31]). It was originally used to treat acute pancreatitis or hyperthermia ([@B22]; [@B61]). Subsequently, more studies revealed its use in anti-inflammation and the protection of liver function as well as in cardiopulmonary bypass and lung disease treatment ([@B45]; [@B29]). In such conditions, UTI can inhibit the inflammatory response, scavenge oxygen free radicals, and shorten the time of tracheal intubation and ventilation ([@B59]; [@B20]). At present, UTI has been evidenced to provide an attractive "rescue" therapeutic option for endotoxin-related inflammatory disorders such as disseminated intravascular coagulation (DIC), acute lung injury, and acute liver injury ([@B21]). Recently, UTI has been demonstrated to play a vital role in sepsis. It is well known that the immune state of sepsis patients undergoes complex changes from the onset of hyper-inflammatory response in the early phase to the immune paralysis in the late phase. To date, no drug has been specifically approved to treat sepsis in human. Recent studies show that UTI has the capacity to reduce inflammation and protect cells and has a potential survival benefit in sepsis and MODS ([@B31]; [@B3]; [@B4]). In the past, the research on UTI treatment for sepsis has mainly been conducted in China, and the results suggested UTI administration can reduce sepsis patient mortality. In 2014, a randomized, controlled, double-blind, and multi-center trial was conducted in India, which revealed the survival benefit of UTI in patients with sepsis ([@B26]). A meta-analysis of the effects of UTI combined with thymosin α1 revealed a reduction in mortality. To better clarify the efficacy of UTI or thymosin α1 administration on sepsis patients, we pooled the RCTs involving treatment with UTI alone. In this meta-analysis, 13 relevant RCTs from three countries and two prospective studies were included. The results showed that in patients with sepsis or septic shock UTI was associated with a significant decrease in all-cause mortality and improvements in both inflammatory cytokine profiles and APACHE II scores. Mortality is the most important index for efficacy evaluation. Studies conducted in sepsis models support that UTI is capable of reducing sepsis-related mortality. The survival benefits were also observed in most clinical trials conducted in different countries. Several trials failed to achieve positive results, probably owing to an insufficient sample size and differences in patients, trials design, and other clinical factors.

Anti-inflammation is one of the most important properties of UTI. It is well known that systemic inflammatory response plays a key role in organ damage or death in sepsis. Agents directed at a single inflammatory mediator have not been shown to have a protective effect in sepsis patients. These results suggest that a single anti-inflammatory agent cannot disrupt the complicated inflammatory network. However, the removal of blood mediators by continuous renal replacement therapy (CRRT) facilitated the achievement of a survival benefit in patients with sepsis or septic shock ([@B32]; [@B41]). Similarly with CRRT, UTI demonstrated a capacity to decrease diverse inflammatory mediator factors such as IL-1, IL-8, IL-6, HMGB1, and other mediators. UTI also inhibits inflammation by suppressing the infiltration of neutrophils and release of elastase and inflammatory mediators from neutrophils. UTI can also suppress MAPK-signaling pathway, which mediates the release of inflammatory cytokines such as TNF-α, IL-1, and IL-6 ([@B21]; [@B12]). Recently, a retrospective study of 263 critically ill patients with sepsis found that 28-day mortality decreased significantly with UTI ([@B58]). The authors concluded that 35% of the total effect of UTI was associated with the reduction in C-reactive protein (CRP), a major marker of inflammation.

Anti-apoptosis is another property of UTI. It has been observed that UTI can reduce apoptosis of endothelial cells, lymphocytes, intestinal epithelium, neurons, and renal cells during different diseases and in animal models ([@B27]). It is well known that there are many immune cells, including lymphocytes, monocytes, and dendritic cells that undergo apoptosis during sepsis. It has been confirmed that UTI can protect cells from apoptosis though anti-oxidation and reduction of mitochondrial damage. It is known that apoptosis contributes to immunoparalysis and death of sepsis patients ([@B18]; [@B19]; [@B5]). Anti-apoptosis in sepsis models, *via* increase in Bcl-2 expression or blocking of CD95, reduced the incidence of sepsis-related mortality ([@B18]; [@B60]; [@B47]; [@B33]). In clinical trials, anti-immune cell apoptosis with anti-PD-1 or anti-PD-L1 also showed potential in sepsis treatment ([@B60]; [@B38]). These studies suggest that cell protection may also be involved in UTI-related survival benefit in patients with sepsis.

Limitations {#s5}
===========

Although this meta-analysis reveals the potential benefits of UTI inpatients with sepsis, these trials were conducted mainly in single centers and the sample sizes were small. Recently, a retrospective observational study conducted in a single intensive care unit (ICU) by Uchida et al. ([@B50]) found that UTI was not associated with a mortality benefit in elderly patients with established multiple organ failure from a variety of causes, only a minority of which were sepsis related. However, UTI use was associated with reduced time on both mechanical ventilators and vasoactive drugs. Thus, multicenter, large sample, randomized clinical trials are still urgently needed to further evaluate the effects of UTI in patients with sepsis. At present, ADJunctive Ulinastatin in Sepsis Treatment in China (ADJUST study), a large sample, multi-center, double-blind, randomized, parallel-group, placebo-controlled trial is being conducted in mainland China ([@B25]). The aim of this trial is to further evaluate the efficacy and safety profiles of UTI.

Conclusions {#s6}
===========

UTI is associated with reductions in both all-cause mortality and the incidence of MODS, and improvements in both APACHE II scores and inflammatory cytokine profiles in patients with sepsis, severe sepsis, or septic shock. Large high quality RCTs are needed to confirm these promising results of UTI in sepsis and septic shock.
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